


(U) Emerging Trend: Fake Xanax[®] Tablets Containing Cyclopropylfentanyl, Methamphetamine, and FUB-AKB48



DEA
BULLETIN



(U) This DEA Bulletin is based on preliminary reporting and may be subject to updating as additional information becomes available.

DEA-PHX-BUL-179-18
AUGUST 2018

(U) Event

(U//DSEN/LES) The increasing demand for opioids in the United States coupled with the availability of fentanyl presents a significant public health risk and negatively impacts officer safety. In 2018, the Arizona High Intensity Drug Trafficking Area (HIDTA) Counter Narcotics Alliance (CNA) task force seized tablets that appeared to be Xanax[®] but actually contained a combination of cyclopropylfentanyl, methamphetamine, and a synthetic cannabinoid chemical.

(U) Significance

(U//LES) This is the first seizure reported to the Arizona HIDTA of fake Xanax[®] tablets containing a cyclopropylfentanyl/methamphetamine combination, as well as being the first reported seizure containing a synthetic cannabinoid.


(U) Details

(U) Fake Xanax[®] Tablets

(U//LES) An investigation conducted by the Arizona HIDTA CNA task force resulted in the seizure of two plastic bags containing 76 rectangular white tablets imprinted with "XANAX" on one side and the number "2" on the reverse side. The tablet imprints and color were consistent with pharmaceutically manufactured 2 milligram Xanax[®] tablets. Upon closer examination, the tablets varied in thickness and from white to off-white in color. In addition, some of the tablets had an inverted "2" imprinted on the reverse side.

(U) LAW ENFORCEMENT SENSITIVE: The information marked (U//LES) in this document is the property of the Drug Enforcement Administration (DEA) and may be distributed within the federal government (and its contractors), U.S. intelligence, law enforcement, public safety or protection officials, and individuals with a need to know. Distribution beyond these entities without DEA authorization is prohibited. Precautions should be taken to ensure this information is stored and/or destroyed in a manner that precludes unauthorized access. Information bearing the LES caveat may not be used in legal proceedings without first receiving authorization from the DEA. Recipients are prohibited from subsequently posting the information marked LES on a website on an unclassified network without first obtaining DEA approval. Written requests for approval may be sent via unclassified email to DEA.IntelligenceProducts@usdoj.gov.

(U//LES) Figure 1. Fake Xanax® tablets shown to vary in thickness.



Source: Arizona High Intensity Drug Trafficking Area

(U//LES) On June 1, 2018, the Tucson Police Department crime laboratory analyzed 10 of the tablets from the seizure. Seven of the tablets contained a usable amount of cyclopropylfentanyl (a fentanyl analog); one tablet contained cyclopropylfentanyl and methamphetamine; one tablet contained FUB-AKB48 (a synthetic cannabinoid chemical); and no dangerous drugs were detected in the remaining tablet.

(U//LES) Figure 2. Fake Xanax® tablets showing inverted “2” imprint.



(U) Source: Arizona High Intensity Drug Trafficking Area

(U//DSEN) As per the Drug Enforcement Administration Fentanyl Signature Profiling Program (FSPP) Report dated July 2018, “. . . a lethal dose of fentanyl is postulated to be about 2 milligrams.”

U//DSEN: Information marked (U//DSEN) indicates DEA reporting at the Law Enforcement Sensitive (LES) level.

(U) This product was prepared by the DEA Phoenix Field Division. Comments and questions may be addressed to the Chief, Analysis and Production Section at DEA.IntelligenceProducts@usdoj.gov.



DEA Intelligence Product Feedback Database



Name of Organization: _____
 Point of Contact: _____ Telephone Number: _____
 Email: _____

DEA Product #: DEA- _____
 Title: _____

	Very Satisfied	Somewhat Satisfied	Neither Satisfied nor Dissatisfied	Somewhat Dissatisfied	Very Dissatisfied
Overall satisfaction with DEA Product	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Readability/Understanding of DEA Product	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Value/Usefulness of NNP Product	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Report Increased my Understanding or Knowledge of the report subject	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Product Relevance to my agency's mission	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
How will you use this report? (Check all that apply)	<input type="checkbox"/> Policy Formulation <input type="checkbox"/> Situational Awareness <input type="checkbox"/> Operational Planning <input type="checkbox"/> Training <input type="checkbox"/> Resource Allocation <input type="checkbox"/> Other				

Additional Comments: